Search for Stocks /

Dr Agarwals Health Care Ltd Q3 FY26 – ₹1,976 Cr Revenue, 27% OPM, 112x PE: India’s Eye-Care King or Valuation Cataract?

Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.

1. At a Glance

Dr Agarwals Health Care Ltd is that overachieving topper in the hospital sector who not only sits in the first bench but also corrects the teacher’s spelling. With a market cap of ₹14,272 Cr, current price ₹450, and a P/E of 112, the market is clearly pricing perfection — maybe even LASIK-level clarity.

In Q3 FY26, revenue clocked ₹530 Cr, up 23% YoY, while PAT jumped 51% YoY to ₹33.7 Cr. Operating margins stayed rock-solid at ~27%, which in hospital land is not normal, it’s elite. Over the last 3 months the stock is down ~11.6%, so clearly Mr Market blinked for a second.

But here’s the twist: despite scale, dominance, and margins, ROE is just 4.76%. Yes, you read that right. India’s largest eye-care chain is profitable, growing fast, and yet returns look like a sleepy PSU bank.

So the obvious question: Is this a compounding healthcare machine temporarily misunderstood, or a great business permanently overvalued? Let’s scrub in.


2. Introduction

Eye care is one of those rare healthcare segments where demand doesn’t need marketing. You age → eyesight goes bad → you show up. No discounts. No seasonality. No Instagram ads. Just biology doing its thing.

Dr Agarwals Health Care Ltd entered this space in 2010 and decided not to be just another clinic with a slit lamp and a receptionist. Instead, it built India’s largest organized eye-care chain, commanding ~25% market share, and more than 2x the revenue of the second-largest player. That’s not competition; that’s dominance.

What makes this story spicy is not just scale, but how they scale. This is not Apollo Hospitals with ₹500 Cr hospitals and ICU-heavy infra. This is a hub-and-spoke ophthalmology machine — high volume, repeatable procedures, asset-light expansion, and ruthless standardization.

Cataracts, refractive surgeries, diagnostics, optics — boring individually, deadly powerful together. Add Africa expansion, mergers within promoter entities, and an IPO war chest, and suddenly this isn’t just an eye hospital — it’s a healthcare platform.

But then you see the valuation. And the ROE. And the debt. And you pause mid-surgery. Let’s go deeper.


3. Business Model – WTF Do They Even Do?

Imagine explaining Dr Agarwals to a lazy but smart investor over chai.

They fix eyes. At scale. Very efficiently.

The company runs three types of facilities:

a) Primary Facilities

These are

Read Full 16 Point breakdown. Continue reading →
EduInvesting runs entirely on reader support — ₹360 a year keeps the lights on.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →